Clinical trial
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney…
NCT00095108 · ZymoGenetics, Industry · Completed
Key facts
| NCT number | NCT00095108 |
|---|---|
| Title | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer |
| Official title | A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Recombinant Human Interleukin-21 (rIL-21) in Subjects With Metastatic Melanoma or Metastatic Renal Cell Carcinoma |
| Lead sponsor | ZymoGenetics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma, Kidney Neoplasms, Metastases |
| Intervention type | Drug |
| Interventions | Recombinant Human Interleukin-21 |
| Enrollment | 43 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Nov 1, 2004 |
| Last update posted | Mar 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: